1. Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring?
   Mara S. Serafini et al, 2024, The Journal of Liquid Biopsy CrossRef
2. Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial
   Joanne Chiu et al, 2023, BMC Medicine CrossRef
3. A Concise Overview of Circulating Tumor DNA Detection for Solid Tumors
   Eric Goold et al, 2024, Advances in Molecular Pathology CrossRef
4. Understanding the Landscape of Clinically Available Molecular Testing
   Julia A. Elvin, 2024, Surgical Oncology Clinics of North America CrossRef
5. Glycoproteomics-Based Liquid Biopsy: Translational Outlook for Colorectal Cancer Clinical Management in Southeast Asia
   Gaayathri Kumarasamy et al, 2023, Future Oncology CrossRef
6. Use of Circulating Tumor DNA to Guide Decision-making in Adjuvant Colon Cancer
   Zachary Gottschalk et al, 2024, Current Oncology Reports CrossRef
7. Use of ctDNA in early breast cancer: analytical validity and clinical potential
   François Panet et al, 2024, npj Breast Cancer CrossRef
8. Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay
   Tadayoshi Hashimoto et al, 2024, International Journal of Clinical Oncology CrossRef